Cyclooxygenase products and atherosclerosis

Drug Discovery Today: Therapeutic Strategies

Volumn 5, Issue 1, 2008, Pages 25-36

  Linton, MacRae F ^a   Fazio, Sergio ^a  

^a Atherosclerosis Research Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; ANGIOTENSIN II; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; G PROTEIN COUPLED RECEPTOR; GELATINASE B; ICOSANOID; INDOMETACIN; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC; TERUTROBAN; THROMBOXANE A2;

ABDOMINAL AORTA ANEURYSM; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD VESSEL REACTIVITY; BONE MARROW CELL; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CELL FUNCTION; CELL TYPE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; ENDOTHELIUM CELL; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENE DELETION; HEART ANEURYSM; HEART PROTECTION; HUMAN; LOW DRUG DOSE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 56449086128     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2008.05.006     Document Type: Review

References (107)

1. Smith W.L., and Marnett L.J. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim. Biophys. Acta 1083 (1991) 1-17
2. DuBois R.N., et al. Cyclooxygenase in biology and disease. FASEB J. 12 (1998) 1063-1073
3. Raz A., et al. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J. Biol. Chem. 263 (1988) 3022-3028
4. Reed D.W., et al. In vivo and in vitro expression of a non-mammalian cyclooxygenase-1. Prostaglandins 52 (1996) 269-284
5. Wu K.K. Cyclooxygenase-2 induction in congestive heart failure friend or foe?. Circulation 98 (1998) 95-96
6. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature - New Biol. 231 (1971) 232-235
7. Picot D., et al. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367 (1994) 243-249 [see comment]
8. Grosser T., et al. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116 (2006) 4-15
9. Hennekens C.H., et al. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 96 (1997) 2751-2753
10. Moncada S., et al. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1 (1977) 18-20
11. Vane J.R. Inhibitors of prostaglandin, prostacyclin, and thromboxane synthesis. Adv. Prostaglandins Thromb. Res. 4 (1978) 27-44
12. FitzGerald G.A., and Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345 (2001) 433-442
13. Francois H., et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2 (2005) 201-207 [see comment]
14. Mitchell J.A., and Warner T.D. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat. Rev. Drug Discov. 5 (2006) 75-86
15. Flavahan N.A. Balancing prostanoid activity in the human vascular system. Trends Pharmacol. Sci. 28 (2007) 106-110
16. Bresalier, R.S. et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 [see comment] [erratum appears in N. Engl. J. Med. 2006 Jul. 13;355(2):221]
17. Hennan J.K., et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104 (2001) 820-825
18. Pidgeon G.P., et al. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 110 (2004) 2701-2707
19. Steffel J., et al. Cyclooxygenase-2 inhibition and coagulation. J. Cardiovasc. Pharmacol. 47 Suppl. 1 (2006) S15-S20
20. Cook J.A. Eicosanoids. Crit. Care Med. 33 12 Suppl. (2005) S488-S491
21. Takayama K., et al. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J. Biol. Chem. 277 (2002) 44147-44154
22. Takayama K., et al. A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling. Circ. Res. 98 (2006) 499-504
23. Norel X., et al. Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat. 74 (2004) 101-112
24. Kennedy C.R., et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat. Med. 5 (1999) 217-220
25. Fabre J.E., et al. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J. Clin. Investig. 107 (2001) 603-610
26. Pavlovic S., et al. Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J. Biol. Chem. 281 (2006) 3321-3328
27. Maciejewski-Lenoir D., et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J. Investig. Dermatol. 126 (2006) 2637-2646
28. Schaloske R.H., et al. Molecular characterization of the lipopolysaccharide/platelet activating factor- and zymosan-induced pathways leading to prostaglandin production in P388D1 macrophages. Biochim. Biophys. Acta 1687 (2005) 64-75
29. Babaev V.R., et al. Conditional knockout of macrophage PPAR [{gamma}] increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1647-1653
30. McAdam B.F., et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitors of COX-2. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 272-277
31. Catella-Lawson F., et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289 (1999) 735-741
32. Van Hecken A., et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol. 40 (2000) 1109-1120
33. Tuleja E., et al. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men. Arterioscler., Thromb. Vasc. Biol. 23 (2003) 1111-1115
34. Hetu P.-O., and Riendeau D. Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. Biochem. J. 391 Pt 3 (2005) 561-566
35. Kawka D.W., et al. Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium. Biochim. Biophys. Acta 1771 (2007) 45-54
36. Schonbeck U., et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155 (1999) 1281-1291
37. Baker C.S., et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler., Thromb. Vasc. Biol. 19 (1999) 646-655
38. Belton O., et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102 (2000) 840-845
39. Pratico D., et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 3358-3363
40. Burleigh M.E., et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105 (2002) 1816-1823
41. Ueno N., et al. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J. Biol. Chem. 276 (2001) 34918-34927
42. Wong E., et al. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis 157 (2001) 393-402
43. Topper J.N., et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively upregulated by steady laminar shear stress. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 10417-10422
44. Inoue H., et al. Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler., Thromb. Vasc. Biol. 22 (2002) 1415-1420
45. Voetsch B., et al. Nitric oxide insufficiency and atherothrombosis. Histochem. Cell Biol. 122 (2004) 353-367
46. Feletou M., and Vanhoutte P.M. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am. J. Physiol. - Heart Circ. Physiol. 291 (2006) H985-H1002
47. Verma S., et al. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 104 (2001) 2879-2882
48. Title L.M., et al. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J. Am. College Cardiol. 42 (2003) 1747-1753 [see comment]
49. Bogaty P., et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 110 (2004) 934-939
50. Monakier D., et al. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 125 (2004) 1610-1615
51. Tikiz C., et al. Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease. Acta Medica Okayama 59 (2005) 11-17
52. Chenevard R., et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107 (2003) 405-409 [see comment]
53. Widlansky M.E., et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42 (2003) 310-315
54. McAdam B.F., et al. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation 112 (2005) 1024-1029 [see comment]
55. Hermann M., et al. To the heart of the matter: coxibs, smoking, and cardiovascular risk. Circulation 112 (2005) 941-945 [comment]
56. Babaev V.R., et al. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 113 (2006) 108-117
57. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, and Group I.-S.I.S.O.I.S.C. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2 (1988) 349-360
58. On behalf of the CAST and IST collaborative groups, Chen Z.M., et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial. Stroke 31 (2000) 1240-1249
59. Antiplatelet Trialists' Collaboration, Collins R., et al. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Br. Med. J. 309 (1994) 1215-1217
60. Chesebro J.H., et al. Antitrombotic therapy and progression of coronary artery disease: antiplatelet versus antitrombins. Circulation 86 (1992) III-100-III-111
61. Ridker P.M., et al. Low dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trail. Ann. Intern. Med. 114 (1991) 835-839
62. Ridker P.M., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336 (1997) 973-979
63. Mehta J.L. Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. Clin. Cardiol. 21 (1998) 879-884
64. Bailey J.M., and Butler J. Anti-inflammatory drugs in experimental atherosclerosis. I. Relative potencies for inhibiting plaque formation. Atherosclerosis 17 (1973) 515-522
65. Egan K.M., et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111 (2005) 334-342
66. Ross R. The pathogenesis of atherosclerosis - a perspective for the 1990s. Nature 362 (1993) 801-809
67. Olesen M., et al. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand. Cardiovasc. J. 36 (2002) 362-367
68. Rott D., et al. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J. Am. College Cardiol. 41 (2003) 1812-1819 [comment]
69. Bea F., et al. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc. Res. 60 (2003) 198-204
70. Linton M.F., and Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr. Opin. Pharmacol. 4 (2004) 116-123
71. Burleigh M.E., et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J. Mol. Cell. Cardiol. 39 (2005) 443-452
72. - mice. Surg. Res. 146 (2008) 135-142
73. Metzner J., et al. The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice. J. Mol. Med. 85 (2007) 623-633
74. Reddick, R.L. et al. (1994) Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14, 141-147 [published erratum appears in Arterioscler. Thromb. 1994 May;14(5):839]
75. Nakashima Y., et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14 (1994) 133-140
76. Belton O.A., et al. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108 (2003) 3017-3023
77. Eligini S., et al. Oxidized low density lipoprotein suppresses expression of inducible cyclooxygenase in human macrophages. Arterioscler., Thromb. & Vasc. Biol. 19 (1999) 1719-1725
78. Joseph S.B., et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9 (2003) 213-219
79. Kothapalli D., et al. Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. J. Clin. Investig. 113 (2004) 609-618
80. Linton M.F., et al. Prevention of atherosclerosis in apoE deficient mice by bone marrow transplantation. Science 267 (1995) 1034-1037
81. Babaev V.R., et al. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J. Clin. Invest. 103 (1999) 1697-1705
82. Makowski L., et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7 (2001) 699-705
83. Vane J.R., et al. Cyclooxygenase 1 and 2. Ann. Rev. Phamacol. Toxicol. 38 (1998) 97-120
84. Needleman P., and Isakson P.C. The discovery and function of COX-2. J. Rheumatol. 24 (1997) 6-8
85. Masferrer J.L., et al. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest. 86 (1990) 1375-1379
86. Michelsen K.S., et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10679-10684
87. Peters W., and Charo I.F. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr. Opin. Lipidol. 12 (2001) 175-180
88. Hinson R.M., et al. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 4885-4890
89. Kim C.J., et al. Polymerase chain reaction-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tumor necrosis factor-alpha and interleukin-1 beta. Arterioscler., Thromb. Vasc. Biol. 20 (1976) 1976-1982
90. Litovsky S., et al. Superparamagnetic iron oxide-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tissue necrosis factor-alpha, interleukin-1beta, and interferon-gamma. Circulation 107 (1545) 1545-1549
91. Blessing E., et al. Lesion progression and plaque composition are not altered in older apoE-/- mice lacking tumor necrosis factor-alpha receptor p55. Atherosclerosis 176 (2004) 227-232
92. Schreyer, S.A. et al. (2002) Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J. Biol. Chem. 277, 12364-12368
93. Hirsch A.T., et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113 (2006) e463-654
94. Daugherty A., et al. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Investig. 105 (2000) 1605-1612 [see comment]
95. King V.L., et al. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler., Thromb. Vasc. Biol. 26 (2006) 1137-1143 [see comment]
96. Gitlin J.M., et al. Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc. Res. 73 (2007) 227-236
97. Cheng Y., et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296 (2002) 539-541
98. Kobayashi T., et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J. Clin. Investig. 114 (2004) 784-794
99. Egan K.M., et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306 (2004) 1954-1957
100. Cheng Y., et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Investig. 116 (2006) 1391-1399
101. Cayatte A.J., et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler., Thromb. Vasc. Biol. 20 (2000) 1724-1728
102. Zhuge X., et al. Protection of atherogenesis in thromboxane A2 receptor-deficient mice is not associated with thromboxane A2 receptor in bone marrow-derived cells. Biochem. Biophys. Res. Commun. 351 (2006) 865-871
103. Sampey A.V., et al. Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2. Arthritis Res. Ther. 7 (2005) 114-117
104. Wang M., et al. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 14507-14512
105. Cipollone F., et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104 (2001) 921-927
106. Cipollone F., et al. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1925-1931
107. Hata A.N., and Breyer R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103 (2004) 147-166